MAPT mutations in amyotrophic lateral sclerosis: clinical, neuropathological and functional insights

Archive ouverte

de Bertier, Sibylle | Lautrette, Géraldine | Amador, Maria-Del-Mar | Miki, Tomoko | Boillée, Séverine | Lobsiger, Christian Stefan | Bohl, Delphine | Darios, Frederic | Machat, Selma | Duchesne, Mathilde | Vourc’h, Patrick | Fauret-Amsellem, Anne-Laure | Corcia, Philippe | Guy, Nathalie | Couratier, Philippe | Seilhean, Danielle | Millecamps, Stéphanie

Edité par CCSD ; Springer Verlag -

International audience. Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are part of a well-established disease continuum, underpinned by TDP43-pathology. In contrast, the clinical manifestations of Tau-linked disorders are typically limited to cognitive phenotypes or atypical parkinsonism, although few reports describe motor neuron involvement associated with MAPT (microtubule-associated protein Tau) mutations. This study aimed to investigate the contribution of MAPT to the ALS phenotype.Methods: We analyzed a whole-exome sequencing database comprising 470 ALS patients and explored the pathogenicity of the identified variants through familial, clinical, neuropathological, and cellular studies.Results: We identified two missense variants in the Tau repeat domains: the novel p.I308T variant, in a patient with earlyonset ALS, and the p.P364S mutation in three families with spinal-or respiratory-onset ALS. Segregation of this mutation with disease could be confirmed in two affected cousins. The observation of p.P364S patient's tissue showed accumulations of hyperphosphorylated Tau in various brain regions, prominent in the motor cortex with Lewy body-like inclusions, along with a C-terminal cleaved form of Tau in muscle. In NSC-34 motor neuron cells expressing p.I308T or p.P364S mutants, Tau was discontinuous along the neurites, with clusters of mitochondria resulting from impaired mitochondrial motility.Conclusion These findings expand the molecular understanding of ALS to include MAPT mutations. MAPT analysis should be incorporated into ALS genetic screening, particularly in patients with a familial history of the disease. Recognizing the full spectrum of MAPT-linked neurodegenerative diseases is of considerable interest, given the ongoing efforts to develop MAPT-targeted therapies.

Suggestions

Du même auteur

Novel UBQLN2 mutations linked to Amyotrophic Lateral Sclerosis and atypical Hereditary Spastic Paraplegia phenotype through defective HSP70-mediated proteolysis

Archive ouverte | Teyssou, Elisa | CCSD

International audience. Mutations in UBQLN2 have been associated with rare cases of X-linked juvenile and adult forms of amyotrophic lateral sclerosis (ALS) and ALS linked to frontotemporal dementia (FTD). Here, we ...

Impact of a frequent nearsplice SOD1 variant in Amyotrophic Lateral Sclerosis: optimizing SOD1 genetic screening for gene therapy opportunities

Archive ouverte | Muratet, François | CCSD

International audience. Objective Mutations in superoxide dismutase 1 gene ( SOD1) , encoding copper/zinc superoxide dismutase protein, are the second most frequent high penetrant genetic cause for amyotrophic later...

Genetic screening of ANXA11 revealed novel mutations linked to Amyotrophic Lateral Sclerosis

Archive ouverte | Teyssou, Elisa | CCSD

International audience. ANXA11 mutations have previously been discovered in Amyotrophic Lateral Sclerosis (ALS) motor neuron disease. To confirm the contribution of ANXA11 mutations to ALS, a large exome dataset obt...

Chargement des enrichissements...